prikaz prve stranice dokumenta Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
  Preuzmi
PDF 1.06 MB
Znanstveni rad - Izvorni znanstveni rad
Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
Scientific Reports, 10 (2020), 1; 10049. https://doi.org/10.1038/s41598-020-67351-5
Nikolac Perković, Matea; Šagud, Marina; Živković, Maja; Uzun, Suzana; Nedić Erjavec, Gordana; Kozumplik, Oliver; Švob Štrac, Dubravka; Mimica, Ninoslav; Mihaljević Peleš, Alma; Pivac, Nela

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Nikolac Perković, M., Šagud, M., Živković, M., Uzun, S., Nedić Erjavec, G., Kozumplik, O. ... Pivac, N. (2020). Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Scientific Reports, 10. (1). doi: 10.1038/s41598-020-67351-5

Nikolac Perković, Matea, et al. "Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia." Scientific Reports, vol. 10, br. 1, 2020. https://doi.org/10.1038/s41598-020-67351-5

Nikolac Perković, Matea, Marina Šagud, Maja Živković, Suzana Uzun, Gordana Nedić Erjavec, Oliver Kozumplik, Dubravka Švob Štrac, Ninoslav Mimica, Alma Mihaljević Peleš i Nela Pivac. "Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia." Scientific Reports 10, br. 1 (2020). https://doi.org/10.1038/s41598-020-67351-5

Nikolac Perković, M., et al. (2020) 'Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia', Scientific Reports, 10(1). doi: 10.1038/s41598-020-67351-5

Nikolac Perković M, Šagud M, Živković M, Uzun S, Nedić Erjavec G, Kozumplik O, i sur.. Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Scientific Reports [Internet]. 22.06.2020. [pristupljeno 22.11.2024.];10(1). doi: 10.1038/s41598-020-67351-5

M. Nikolac Perković, et al., "Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia", Scientific Reports, vol. 10, br. 1, Lipanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:008806. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:008806
Podaci o radu
Naslov (engleski)Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
AutorMatea Nikolac Perković
AutorMarina Šagud
AutorMaja Živković
AutorSuzana Uzun
AutorGordana Nedić Erjavec
AutorOliver Kozumplik
AutorDubravka Švob Štrac
AutorNinoslav Mimica
AutorAlma Mihaljević Peleš
AutorNela Pivac
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PSIHIJATRIJU I PSIHOLOŠKU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Sažetak (engleski)
Antipsychotic drugs target primarily dopaminergic system which makes catechol-O-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. 521 Caucasian patients with schizophrenia received a monotherapy with olanzapine (10-20 mg/day; N = 190), risperidone (3-6 mg/day; N = 99), or clozapine (100-500 mg/day; N = 102). The fourth group (N = 130) consisted of patients receiving haloperidol (3-15 mg/day), fluphenazine (4-25 mg/day) or quetiapine (50-800 mg/day). Treatment response was defined as a 50% reduction from the baseline positive and negative syndrome scale (PANSS) total and subscale scores, but also as an observed percentage reduction from the initial PANSS0-6 total and subscale scores. Carriers of the COMT rs4680 A allele and carriers of the COMT rs4680-rs4818 C-A haplotype block had greater reduction in the PANSS total scores following olanzapine treatment, compared to carriers of the COMT rs4680 GG genotype and other COMT rs4680-rs4818 haplotypes. The COMT rs4680 A allele, and COMT rs4680-rs4818 C-A haplotype, were significantly associated with therapeutic response in patients treated with olanzapine, but not in patients treated with other antipsychotics.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaScientific Reports
Brojčani podacivol. 10, br. 1, 10049
e-ISSN2045-2322
DOIhttps://doi.org/10.1038/s41598-020-67351-5
URN:NBNurn:nbn:hr:105:008806
Datum objave publikacije2020-06-22
URL dokumentahttp://www.nature.com/articles/s41598-020-67351-5
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-03-24 10:40:57